

Jian Fang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2910947/jian-fang-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

542
citations

12
h-index

22
g-index

57
ext. papers

1,016
ext. citations

4.7
avg, IF

3.43
L-index

#	Paper	IF	Citations
43	A novel third generation EGFR tyrosine kinase inhibitor Abivertinib for EGFR T790M mutant Non-Small Cell Lung Cancer: a multicenter phase1/2 study. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
42	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. <i>Frontiers in Oncology</i> , 2021 , 11, 607531	5.3	2
41	Small Cell Size Circulating Aneuploid Cells as a Biomarker of Prognosis in Resectable Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 590952	5.3	1
40	Prognostic factor analysis of patients with small cell lung cancer: Real-world data from 988 patients. <i>Thoracic Cancer</i> , 2021 , 12, 1841-1850	3.2	2
39	Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0
38	Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 305-314	35.1	70
37	Comparison of endostatin combined with PT-DC versus bevacizumab combined with PT-DC in the first-line treatment of advanced lung adenocarcinoma: a retrospective propensity score-matched cohort study. <i>Annals of Palliative Medicine</i> , 2021 , 10, 7847-7856	1.7	1
36	Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. <i>Translational Lung Cancer Research</i> , 2021 , 10, 981-994	4.4	4
35	Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 2109-2120	8.9	10
34	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 1154-1164	35.1	14
33	Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. <i>Cancer Biology and Medicine</i> , 2021 ,	5.2	6
32	Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.. <i>Thoracic Cancer</i> , 2021 ,	3.2	1
31	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China.. <i>Thoracic Cancer</i> , 2021 ,	3.2	4
30	Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients. <i>Cancer Cell International</i> , 2020 , 20, 590	6.4	
29	A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. <i>International Journal of Cancer</i> , 2020 , 147, 3453-3460	7.5	12
28	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study. <i>Lung Cancer</i> , 2020 , 146, 252-262	5.9	4
27	Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1015-1026	8.9	25

26	Pyrotinib in -Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2753-2761	2.2	49
25	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). <i>Journal of Clinical Oncology</i> , 2020 , 38, 9519-9519	2.2	30
24	A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9583-9583	2.2	1
23	Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. <i>Journal of Thoracic Disease</i> , 2020 , 12, 5324-5335	2.6	5
22	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). <i>Journal of Thoracic Oncology</i> , 2020 , 15, 1636-1646	8.9	75
21	Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations. <i>Journal of Pharmacy and Pharmacology</i> , 2020 , 72, 1528-1535	4.8	2
20	Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring exon 14 skipping mutation: a case report. <i>OncoTargets and Therapy</i> , 2019 , 12, 7323-7328	4.4	11
19	Salvage treatment with anlotinib for advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 1590-1596	2.0	20
18	Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer. <i>Cancer Communications</i> , 2019 , 39, 20	9.4	4
17	A study of ALK-positive pulmonary squamous-cell carcinoma: From diagnostic methodologies to clinical efficacy. <i>Lung Cancer</i> , 2019 , 130, 135-142	5.9	5
16	Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019 , 8, 989-999	4.4	16
15	Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma. <i>Thoracic Cancer</i> , 2019 , 10, 17-23	3.2	2
14	Efficacy, safety and predictive indicators of apatinib after multilines treatment in advanced nonsquamous nonsmall cell lung cancer: Apatinib treatment in nonsquamous NSCLC. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 446-452	1.9	18
13	A comparison of QuantStudioBD Digital PCR and ARMS-PCR for measuring plasma EGFR T790M mutations of NSCLC patients. <i>Cancer Management and Research</i> , 2018 , 10, 115-121	3.6	11
12	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1743-1749	8.9	7
11	Efficacy and toxicities of gemcitabine and cisplatin combination chemotherapy in advanced thymoma and thymic carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20007-e20007	2.2	
10	Prognostic value of a 12-gene signature in platinum-based chemotherapy treated SCLC.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20011-e20011	2.2	
9	Icotinib as first-line or maintenance therapy in patients with advanced lung adenocarcinoma with positive EGFR mutation and the influence of cytokines shift on survival.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20658-e20658	2.2	

8	Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20574-e20574	2.2	
7	Clinical characteristics associated with non-small-cell lung cancer harboring ALK rearrangements in Chinese patients. <i>Future Oncology</i> , 2016 , 12, 1243-9	3.6	4
6	Clinical characteristics associated with metastatic NSCLC harboring ALK rearrangements in Chinese patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e20628-e20628	2.2	
5	Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. <i>Thoracic Cancer</i> , 2015 , 6, 534-8	3.2	86
4	A Retrospective Study of Stage I to IIIa Lung Adenocarcinoma After Resection: What Is the Optimal Adjuvant Modality for Patients With an EGFR Mutation?. <i>Clinical Lung Cancer</i> , 2015 , 16, e173-81	4.9	20
3	Dynamic changes of circulating tumor cells during chemotherapy as a prognostic factor in patients with advanced lung cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22024-e22024	2.2	
2	Retrospective study of surgery versus non-surgical management in limited-disease small cell lung cancer. <i>Thoracic Cancer</i> , 2014 , 5, 405-10	3.2	6
1	Decreased maspin combined with elevated vascular endothelial growth factor C is associated with poor prognosis in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2014 , 5, 383-90	3.2	5